Rohto Pharmaceutical Co.,Ltd. (4527.T)

Rohto Pharmaceutical Co.,Ltd. (4527.T) — VMCI valuation read

Rohto Pharmaceutical Co.,Ltd. (4527.T) carries a VMCI composite of 50/100, 0 points above the Consumer Defensive sector median of 50. Among mid-cap names, that gap places 4527.T in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 4527.T insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 4527.T trades at 14.0x earnings, 22% below the Consumer Defensive median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Consumer Defensive 12.0x. Quality: ROIC of 14.0% sits 4.0pp above the Consumer Defensive median (10.0%). Risk: net debt to EBITDA of -0.2x leaves covenant headroom, the line to track on Rohto Pharmaceutical Co.,Ltd.'s next 10-Q.

4527.T rose 1.6% over the trailing 7 days, with a +7.1% read on a 30-day basis.